secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-05-14T20:31:51+00:00
Accession:  0001104659-26-061241
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen CMO Huma Qamar departs; Mohamed Genead named acting interim CMO
----------------------------------------------------------------------

- Huma Qamar separated from Ocugen as Chief Medical Officer effective May 8, 2026.
- Mohamed Genead, M.D., appointed Acting/Interim Chief Medical Officer effective May 8, 2026.
- No reason for departure or transition details were disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/0001104659-26-061241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/tm2614578d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer